12
Participants
Start Date
July 20, 2023
Primary Completion Date
August 31, 2029
Study Completion Date
August 31, 2029
Cyclophosphamide
Given IV
Fludarabine
Given IV
Autologous Anti-H3.3K27M TCR-expressing T-cells
Given IV
RECRUITING
University of California, San Francisco, San Francisco
The V Foundation
OTHER
Parker Institute for Cancer Immunotherapy
OTHER
Alliance for Cancer Gene Therapy
OTHER
University of California, San Francisco
OTHER